#ExpertTalk: CNM-Au8 Long-term Evidence & EAP Program Update | Rob Etherington & Dr. Marjan Sepassi
Welcome to another insightful episode of #ExpertTalk by EverythingALS! In this session, we bring you the latest updates on CNM-Au8, a groundbreaking therapeutic candidate from Clene Nanomedicine. Our expert speakers, Rob Etherington (Chief Executive Officer, Clene Nanomedicine) and Dr. Marjan Sepassi (Vice President, Medical Affairs, Clene Nanomedicine), delve into the long-term evidence supporting CNM-Au8 and the Expanded Access Program (EAP) update. Discover how Clene Nanomedicine’s innovative approach to neurodegenerative diseases is paving new pathways for ALS treatment. Rob Etherington shares strategic insights, while Dr. Marjan Sepassi provides a medical perspective on CNM-Au8’s clinical impact and the value of the EAP for patients and caregivers. What You’ll Learn in This Episode: Key findings from long-term evidence on CNM-Au8’s efficacy Insights on the Expanded Access Program (EAP) for ALS patients Strategic and medical perspectives from Clene Nanomedicine’s leadership team Don’t miss this chance to stay informed about the future of ALS treatment. Watch now and be part of the conversation. Timestamps: ► 0:00 Introduction ► 2:15 Meet the Experts: Rob Etherington & Dr. Marjan Sepassi ► 5:30 What is CNM-Au8? ► 12:45 Long-term Evidence and Clinical Insights ► 25:10 Expanded Access Program (EAP) Update ► 40:00 Q&A with Viewers Follow EverythingALS: ► Website: https://www.everythingals.org ► Twitter: https://x.com/everything_als ► LinkedIn: / everythingals ► Facebook: / everythingals ► Subscribe for more Expert Talks: / everythingals #ExpertTalk #EverythingALS #ALSResearch #CleneNanomedicine #CNMAu8 #ALSUpdate #ALSCommunity #NeurodegenerativeDisease #ALSClinicalTrials #RobEtherington #MarjanSepassi #ExpandedAccessProgram #ALSBreakthroughs #MedicalResearch #HealthcareInnovation If you’re interested in the latest developments in ALS research and treatment, hit the like button, subscribe, and turn on notifications for future updates. Share this video with others who may benefit from this essential information.
Updates & Innovations in ALS Clinical Trial Landscape by Dr. Jinsy Andrews
Dr. Olga Uspenskaya-Cadoz and Dr. James Berry discuss PIONEER-ALS and TDP-43 research.
LIVE: Conan O’Brien speaks at Harvard graduation ceremony (full)
Clara Mattei: capitalism is not natural - it’s enforced
What Job Seekers Really Want: Insights from Our Candidate Survey
Which Cells Drive ALS? New Strategies for Designing Targeted Therapies
HopeUntangled, February 18, 2026
Conan O’Brien Delivers the Commencement Address | Harvard Commencement 2026
Digital Asset Treasuries Under Pressure, IMF Warns of Tokenization Risks | Bloomberg Crypto 4/7/2026
CNM-Au8 Survival, NFLBiomarker, and Phase 3Update with Mr. Rob Etherington and Dr. MarjanSepassi
Unlocking the Origins of ALS Through Large-Scale Patient Data
Signals from the Outer Limits - What I've Learned from Slow Progressors and ALS Reversals
A Breath of Fresh Air: Targeted Screening and Management of COPD in Primary Care by Dr Mohit Bhutani
Multicenter Consensus Treatment Plan for Immunosuppression after Pediatric Liver Transplant-Webinars
Leading in the Age of AI: A Conversation with NVIDIA CEO Jensen Huang | Global Conference 2026
Something is jamming GPS over Europe. Here's what we found
Estate Planning 101: Three Big Decisions
The PREVAiLS Study: Pridopidine for the Treatment of ALS
AlphaFold - The Most Useful Thing AI Has Ever Done
